Cuprizone short-term exposure: Astrocytic IL-6 activation and behavioral changes relevant to psychosis

Neurobiology of Disease

Volumn 59, Issue , 2013, Pages 63-68

  Tezuka, Tomoaki ^a   Tamura, Makoto ^a   Kondo, Mari A ^b   Sakaue, Masaki ^a   Okada, Kinya ^a   Takemoto, Kana ^a   Fukunari, Atsushi ^a   Miwa, Keiko ^a   Ohzeki, Hiromitsu ^a   Kano, Shin ichi ^b   Yasumatsu, Hiroshi ^a   Sawa, Akira ^b   Kajii, Yasushi ^a,c  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABBVIE INC   (United States)

Author keywords

Astrocyte; Cytokine; Inflammation; Interleukin 6; Schizophrenia

Indexed keywords

CUPRIZONE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; MESSENGER RNA; METHAMPHETAMINE; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR CHANGE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; IMMUNOHISTOCHEMISTRY; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; UPREGULATION; WORKING MEMORY;

ASTROCYTE; CYTOKINE; INFLAMMATION; INTERLEUKIN-6; SCHIZOPHRENIA;

ANIMALS; ASTROCYTES; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHELATING AGENTS; COPPER; CUPRIZONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HALLUCINOGENS; HYPERKINESIS; INTERLEUKIN-6; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; PHENCYCLIDINE; PSYCHOTIC DISORDERS; TIME FACTORS;

EID: 84881108687     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.07.003     Document Type: Article

References (46)

1. Arnett H.A., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
2. Barker G.R., et al. Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J. Neurosci. 2007, 27:2948-2957.
3. Ben Achour S., Pascual O. Glia: the many ways to modulate synaptic plasticity. Neurochem. Int. 2010, 57:440-445.
4. Benros M.E., et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168:1303-1310.
5. Bowman M.B., Lewis M.S. The copper hypothesis of schizophrenia: a review. Neurosci. Biobehav. Rev. 1982, 6:321-328.
6. Coughlin J.M., et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol. Psychiatry 2013, 18:10-11.
7. Doorduin J., et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
8. Duan J., et al. Genome-wide approaches to schizophrenia. Brain Res. Bull. 2010, 83:93-102.
9. Fukumoto H., et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 2010, 30:11157-11166.
10. Gaier E.D., et al. Copper signaling in the mammalian nervous system: synaptic effects. J. Neurosci. Res. 2013, 91:2-19.
11. Garver D.L., et al. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharm. 2003, 28:1515-1520.
12. Glass C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
13. Gregg J.R., et al. Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophr. Res. 2009, 113:277-287.
14. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt 4):593-624.
15. Herran A., et al. Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. Psychiatry Res. 2000, 94:51-58.
16. Kikawada T., et al. Trehalose transporter 1, a facilitated and high-capacity trehalose transporter, allows exogenous trehalose uptake into cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11585-11590.
17. Kopec K., et al. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem. Pharmacol. 2010, 80:1407-1417.
18. Kornhuber J., et al. Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. Biol. Psychiatry 1994, 36:31-34.
19. Kousaka A., et al. The distribution and characterization of endogenous protein arginine N-methyltransferase 8 in mouse CNS. Neuroscience 2009, 163:1146-1157.
20. Koutsoudaki P.N., et al. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci. Lett. 2009, 451:83-88.
21. Kreisl W.C., et al. A genetic polymorphism for translocator protein 18kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J. Cereb. Blood Flow Metab. 2012, 33:53-58.
22. Lin A., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32:9-15.
23. Liu L., et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
24. Makinodan M., et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:978-985.
25. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
26. Miller B.J., et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
27. Potvin S., et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
28. Purcell S.M., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
29. Schlief M.L., Gitlin J.D. Copper homeostasis in the CNS: a novel link between the NMDA receptor and copper homeostasis in the hippocampus. Mol. Neurobiol. 2006, 33:81-90.
30. Shi J., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
31. Shore D., et al. CSF copper concentrations in chronic schizophrenia. Am. J. Psychiatry 1983, 140:754-757.
32. Singh S., et al. Astrocytes and microglia: responses to neuropathological conditions. Int. J. Neurosci. 2011, 121:589-597.
33. Stefansson H., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
34. van Kammen D.P., et al. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1999, 87:129-136.
35. Wang H., et al. Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. Neurosci. Bull. 2013, 29:251-259.
36. Wolf T.L., et al. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr. Res. 2006, 86:167-171.
37. Xiao L., et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 2008, 13:697-708.
38. Xu H., et al. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behav. Neurosci. 2009, 123:418-429.
39. Xu H., et al. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Front. Behav. Neurosci. 2010, 4:8.
40. Xu H., et al. Recovery of behavioral changes and compromised white matter in C57BL/6 mice exposed to cuprizone: effects of antipsychotic drugs. Front. Behav. Neurosci. 2011, 5:31.
41. Yang H.J., et al. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: implications for the pathophysiology of schizophrenia. Brain Res. 2009, 1270:121-130.
42. Yanik M., et al. Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia. Biol. Trace Elem. Res. 2004, 98:109-117.
43. Yolken R.H., Torrey E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008, 13:470-479.
44. Yoshikawa K., et al. Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. Prostaglandins Leukot. Essent. Fat. Acids 2011, 85:43-52.
45. Zatta P., et al. Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol. Life Sci. 2005, 62:1502-1513.
46. Zhang Y., et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res. 2008, 106:182-191.